Publications

The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Rachel E. Laing, Patricia Hess, Yingjie Shen, Jian Wang and Sean X. Hu.
June, 2011
Planning for Uncertainty
Future treatment dynamics in NHL & Implications for strategic planning
Dr Rachel Laing, Olivier Lesueur & Carter Gould.
May, 2011
Etude LEEM Biomarqueurs
Le biomarqueur comme outil de diagnostic compagnon de produits thérapeutiques. Impacts sur la R&D et sur les modèles économiques des industriels de la Santé
Etude réalisée pour le compte du LEEM.
February, 2011
Claude Allary raconte l’histoire de sanofi-aventis
Il évoque les étapes de son développement et dresse un bilan des 40 « premières » années de l'entreprise.
Article de Claude Allary dans Reflets ESSEC.
January, 2011
Using Innovation to Drive Competitive Advantage
BioProcess International.
Claude Allary, Michael Parker, and Sarah Rhodes.
September, 2009
Signs of appetite
Financial Advisory Newsletter
Q2 - 2009
The Big Buy
EBR
« Alain J Gilbert and Meredith Edwards of Bionest Partners examine trends for biotech partnering in 2009 and discuss how to optimise outcomes in these turbulent conditions ».
Spring, 2009
Being patient
Financial Advisory Newsletter
Q1 - 2009
Pharmaceutical Executive
The Business Magazine of Pharma. Vol 28, Number
« Real innovation is the name of the game—products and technologies that specifically meet a previously unmet medical need, and therefore unequivocally attract needed funding. Market access and maintenance are knowledgebased, cross-functional processes, which leading pharma companies must implement immediately ».
November, 2008
Value Destruction
Financial Advisory
Q4 - 2008
1 2 3 4 5